If the first three quarters of 2019 were dominated by pricing fears, the last saw a remarkable comeback for biopharma.
Novo Nordisk took an early step towards genome editing with yesterday’s Bluebird tie-up, and isn’t ruling out a move into conventional gene therapies.
Non-US big biopharma stocks led the way in the third quarter, suggesting that those looking for investment gains would do best to search further afield.
A phase III win for Roche’s satralizumab has added to Alexion’s Soliris woes.
The Astrazeneca spinout is plugging data with its rare disease contender inebilizumab, but Alexion’s Soliris is one step ahead.
Promising mid-stage data with Merck KGaA’s evobrutinib in multiple sclerosis could help the German group carve out a niche for its BTK inhibitor – unless bigger players…
Several large-cap drug stocks registered healthy gains across the third quarter of 2018, signalling investors' growing confidence in biopharma after a disappointing…
Novartis hails the most advanced alpha-directed PI3K inhibitor after success in breast cancer, but it’s not the only one.
Roche targets bispecifics to get ahead in oncology.